Anti-IL-11 Therapy
An emerging anti-fibrotic strategy targeting interleukin-11, a pro-inflammatory cytokine that rises with age and activates fibroblasts. Of particular interest in ovarian aging, where IL-11-driven matrix stiffening appears to be a proximate cause of declining ovarian function.
Evidence Summary
Peer-reviewed, but the ovarian-aging evidence is rodent-interventional with human tissue characterization only. Nature Aging 2026 (Wu et al.) used atomic force microscopy to show human ovarian matrix stiffness rises with age and in chemotherapy-induced premature ovarian insufficiency, PCOS and endometriosis. Integrating human ovarian proteomics with human ovarian fibroblast transcriptomics identified IL-11 - elevated in aging mouse, rat and human ovary - as the fibroblast-activating signal. Genetic deletion of Il11ra1 in mice mitigated age-, POI- and PCOS-associated stiffening and functional decline, single-nuclei RNA-seq confirmed reduced activated-fibroblast fraction, and siIl11 nanoparticles in aged mice and rats reduced stiffness and enhanced fertility. Anti-IL-11 monoclonal antibodies are already in clinical development for fibrotic indications, which makes the translational path unusually short - but no human trial in ovarian aging or reproductive longevity exists, and the safety profile of chronic IL-11 blockade in a healthy aging population is uncharacterized. UPDATE (August 16, 2026): Two peer-reviewed Nature Aging papers extend the ovarian-aging picture beyond IL-11, and one of them complicates the standard model of reserve depletion. (1) Li, Zheng, Zhang et al. (14 August 2026) report a cross-sectional human cohort analysis linking lower physical activity with menopause, and show in mice that exercise delays ovarian aging at least in part by raising adiponectin - with an ADIPONECTIN RECEPTOR AGONIST reproducing the protective effect pharmacologically, without exercise. This is a second druggable ovarian-aging axis alongside IL-11/matrix stiffening, and unlike anti-IL-11 it has a non-pharmacological correlate that can be recommended today. The human arm is observational and cannot exclude reverse causation (declining ovarian function reducing activity); all interventional data are murine and no adiponectin receptor agonist is approved for human use. (2) D'Angelo, Franco-Barranco and Boke (12 August 2026) mapped over 85,000 mouse oocytes in intact ovaries using whole-organ imaging, AI segmentation and modelling, and found the ovary maintains a STABLE FRACTION of newly activated oocytes throughout aging - implying organ-wide feedback control of activation rather than a fixed per-oocyte activation rate. That complicates the intuitive burn-rate model of reserve depletion that underlies a good deal of AMH-based counselling, though whether the same organ-level control operates in human ovaries is untested.
Evidence Scale
Mechanism of Action
IL-11 signals through IL11RA to activate fibroblasts, which secrete extracellular matrix and stiffen tissue. In the ovary, this stiffening of the stroma in which follicles are embedded impairs follicular development and hormone production. IL-11 has separately been implicated in fibrosis of lung, liver, heart and kidney, and in murine work as a general driver of age-related fibro-inflammation.
Who Is This For?
No patient is currently a candidate outside a registered clinical trial. Relevant as background for patients asking about fertility preservation, premature ovarian insufficiency, or reproductive longevity.
Protocol & Dosing
Dose
Not applicable - no approved agent for aging or reproductive indications
Frequency
Not applicable
Duration
Not applicable
Protocol Summary
No clinical protocol for aging or reproductive indications. Anti-IL-11 antibodies are in trials for fibrotic disease; those programs are indication-specific and not transferable.
Interactions & Precautions
Contraindications
- Not clinically available for aging or fertility indications
- Any off-label use outside a trial is unsupported by human evidence
Potential Risks
- •All efficacy data in reproductive aging are rodent
- •Long-term consequences of blocking a pleiotropic cytokine are unknown
- •Risk of premature commercial offering ahead of human data
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
Worth knowing about because patients concerned with reproductive longevity will encounter the headlines. Be precise: human ovarian tissue was measured, but every intervention - Il11ra1 knockout, siIl11 nanoparticles, restored fertility - was in mice and rats. The mechanistic story (age-related fibrosis as a proximate cause of ovarian failure, rather than follicle depletion alone) is genuinely useful for framing conversations about ovarian aging even in the absence of a therapy. Do not offer or endorse off-label anti-IL-11 use for fertility or aging. Updated August 16, 2026: Two additions worth carrying into reproductive-longevity conversations. First, exercise now has a mechanistic ovarian rationale, not just an association - the adiponectin axis (Nature Aging, August 2026). This matters practically because it is the only ovarian-aging lever on this page a patient can act on today; the pharmacological arm (adiponectin receptor agonism) is murine and unavailable. Be careful with the human data: it is cross-sectional, and lower activity in women approaching menopause is at least as plausibly a consequence as a cause. Second, if a patient is anxious about a declining AMH, the whole-ovary mapping work (Nature Aging, August 2026) is a useful nuance - in mice the ovary appears to regulate activation at the organ level rather than burning through a fixed allotment at a fixed rate, which argues against framing AMH as a simple fuel gauge. Do not over-extend it: the finding is murine and does not change how AMH should be interpreted clinically.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Cost & Access
Cost Range
Not commercially available for these indications
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation